Microphysiological system to advance adoptive cell therapy

Adoptive cell therapy has emerged as promising cancer treatment in recent years. Despite its advantages, clinical applications of this patient-specific therapy face, however, many challenges. A novel microfluidic platform, developed by the group of Andreas Hierlemann in collaboration with members from Timm Schroeder’s group, helps to improve the process of identifying potent anti-tumour immune cells and their corresponding targets, bridging the gap between in-vitro and in-vivo studies.